New hope for rare vascular disease: trial tests two experimental drugs
NCT ID NCT07451665
Summary
This study compares two new drugs, vunakizumab and ivarmacitinib, against standard steroid treatment for adults with active Takayasu's arteritis, a rare inflammatory disease of the blood vessels. Researchers will enroll 180 participants across multiple centers to see which treatment helps more patients achieve complete control of their disease by week 52. The main goal is to find safer, more effective long-term management options for this challenging condition.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TAKAYASU ARTERITIS (TAK) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Anzhen Hospital Capital Medical University
Beijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Jiangsu Province Hospital
Nanjing, Jiangsu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Jiaozuo People's Hospital
Jiaozuo, Henan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
-
People's Hospital of Guangxi Zhuang Autonomous Region
Nanning, Guangxi, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
People's Hospital of Ningxia Hui Autonomous Region
Yinchuan, Ningxia, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
People's Hospital of Xinjiang Uygur Autonomous Region
Ürümqi, Xinjiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Shenzhen People's Hospital
Shenzhen, Guangdong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Sichuan Provincial People's Hospital
Chengdu, Sichuan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The Affiliated Hospital of Inner Mongolia Medical University
Hohhot, Neimenggu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The First Affiliated Hospital of Baotou Medical College
Baotou, Neimenggu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The First Affiliated Hospital of Sun Yat-sen University
Guanzhou, Guangdong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The First Hospital of China Medical University
Shenyang, Liaoning, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The First Hospital of Jilin University
Ch’ang-ch’un, Jilin, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The First Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The Second Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Union Hospital Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Xuanwu Hospital Capital Medical University
Beijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.